4th Quarter 2019
Key topics in this quarter’s edition include:
- Trikafta™ (elexacaftor/ tezacaftor/ ivacaftor; ivacaftor) for treatment of cystic fibrosis in patients who have at least one F508del mutation in the CFTR gene
- Adakveo® (crizanlizumab) for reduction of the frequency of vasoocclusive crises in patients with sickle cell disease
- Voxelotor for treatment of hemolytic anemia in patients with sickle cell disease
- AR-101 to reduce the incidence and severity of allergic reactions after accidental exposure to peanut in patients with peanut allergy
Top